Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.

Chetana LimA DoussotM OsseisF EspositoC SalloumJ CalderaroC TournigandD Azoulay

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)

Neoadjuvant Bevacizumab-based chemotherapy was associated with improved OS in patients who underwent liver resection of synchronous CRLM, especially in those who underwent primary tumor resection first.

Keyphrases

liver metastases
end stage renal disease
lymph node
prognostic factors
locally advanced
ejection fraction
chronic kidney disease
newly diagnosed
rectal cancer
peritoneal dialysis